

Active studies

Title	Phase	Tumortype	Line of Therapy	Study Information	Register
First-line immunotherapy using Wilms' tumor protein 1 (WT1)-targeted dendritic cell vaccinations for malignant pleural mesothelioma (MESODEC)	I/II	MPM	1L	<ul style="list-style-type: none"> • Epitheloid mesothelioma • Q3W: Pemetrexed + Cisplatinum + DC vaccination • Ongoing DC vaccination Q4W 	NCT02649829
An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)	I/II	NSCLC PD-L1 ≥ 50%	1L	<ul style="list-style-type: none"> • SoC (+/- anti-PD-1) + PDC*lung01 (Q1W) 	NCT03970746
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)	II/III	NSCLC Stage IIIB-IV non-squamous	1L	<ul style="list-style-type: none"> • Arm A: <ul style="list-style-type: none"> ○ Induction 4x Q3W: Tiragolumab + Atezolizumab + Pemetrexed + Carboplatin/Cisplatinum ○ Maintenance: Q3W: Tiragolumab + Atezolizumab + Pemetrexed • Arm B: <ul style="list-style-type: none"> ○ Induction 4x Q3W: Placebo + Pembrolizumab + Pemetrexed + Carboplatin/Cisplatinum ○ Maintenance: Q3W: Placebo + Pembrolizumab + Pemetrexed 	NCT04619797

<p>A multicenter non-interventional cohort study to evaluate the real-world clinical management and outcomes of patients diagnosed with ALK-positive advanced NSCLC treated with Alectinib (REALEC)</p>	<p>NA</p>	<p>NSCLC ALK+</p>	<p>1L</p>	<ul style="list-style-type: none"> • Observational study • SOC: Alectinib (BID) 	<p>NCT04764188</p>
<p>Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer (M14-239)</p>	<p>II</p>	<p>NSCLC Stage III, IV c-Met+</p>	<p>2L or 3L</p>	<ul style="list-style-type: none"> • Telisotuzumab Vedotin (Q2W) 	<p>NCT03539536</p>
<p>A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8)</p>	<p>III</p>	<p>NSCLC Stage III Unresectable PD-L1 \geq 1%</p>	<p>maintenance treatment after cCRT</p>	<ul style="list-style-type: none"> • Arm A: durvalumab + domvanalimab (Q4W) • Arm B: durvalumab + placebo (Q4W) 	<p>NCT05211895</p>

<p>A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS \geq50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08)</p>	<p>III</p>	<p>NSCLC Stage IIIB, IIIC, IV PD-L1 \geq 50%</p>	<p>1L</p>	<ul style="list-style-type: none"> • Arm 1: Dato-DXd + pembrolizumab (Q3W) • Arm 2: Pembrolizumab (Q3W) 	<p>NCT05215340</p>
<p>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis (ASPEN)</p>	<p>III</p>	<p>NCFB</p>	<p>/</p>	<ul style="list-style-type: none"> • Brensocatib 10 mg (QD) • Brensocatib 25 mg (QD) • Matching placebo 	<p>NCT04594369</p>
<p>Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression \geq 1% and an STK11 Co-mutation (KonTRASt-06)</p>	<p>II</p>	<p>NSCLC KRAS G12C PD-L1 < 1% PD-L1 \geq 1% + STK11</p>	<p>1L</p>	<ul style="list-style-type: none"> • JDQ443 single-agent 400mg (BID) 	<p>NCT05445843</p>

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte)	III	ES-SCLC	1L	<ul style="list-style-type: none"> • Induction: SoC • Maintenance: <ul style="list-style-type: none"> - Arm A: Atezolizumab + Lurbinectedin (Q3W) - Arm B: Atezolizumab (Q3W) 	NCT05091567
--	-----	---------	----	--	-------------

PENDING for activation

Title	Phase	Tumortype	Line of Therapy	Study Information	Register
A Phase 2 Randomized Study of BMS-986207 in Combination with Nivolumab and Ipilimumab as First-line Treatment for Participants with Stage IV Non-Small Cell Lung Cancer (BMS CA020-016)	II	NSCLC Stage IV	1L	<ul style="list-style-type: none"> • Arm A: nivolumab (Q3W) + ipilimumab (Q6W) + BMS-986207 (Q3W) • Arm B: nivolumab (Q3W) + ipilimumab (Q6W) + placebo (Q3W) 	NCT05005273
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer	III	NSCLC unresected Stage I/II N0	-	<ul style="list-style-type: none"> • Experimental: SoC SBRT + Durvalumab Therapy (Main Cohort) • Placebo Comparator: SoC SBRT + Placebo Therapy (Main Cohort) • Experimental: SoC SBRT + Osimertinib Therapy (Osimertinib cohort, single-arm, separate cohort) 	NCT03833154

(PACIFIC-4)					
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)	III	NSCLC Stage IIIb, IIIc, IV PD-L1 TPS <50%	1L	<ul style="list-style-type: none"> • Experimental: Dato-DXd + Pembrolizumab + Platinum Chemotherapy • Experimental: Dato-DXd + Pembrolizumab • Active Comparator: Pembrolizumab + Pemetrexed + Platinum Chemotherapy 	NCT05555732
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)	III	NSCLC EGFR	2L	<ul style="list-style-type: none"> • Experimental: Savolitinib + Osimertinib • Active Comparator: Chemotherapy 	NCT05261399
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into platinum/pemetrexed-based first-line treatment for epithelioid malignant pleural mesothelioma (Immuno-MESODEC)	I/II	MPM	1L	<ul style="list-style-type: none"> • Epithelioid mesothelioma • Q3W: Pemetrexed + platinum + atezolizumab + DC vaccination • Ongoing DC vaccination Q4W + atezolizumab 	TBD

Disease Registry on Patients with Advanced NSCLC harboring METex14 Skipping Alterations (MOMENT)	registry	NSCLC MET ex14		registry	TBD
--	----------	-------------------	--	----------	-----